5 ischemia thumb

ISCHEMIA’s Ripple Effects and Where They Leave Cardiologists

This year’s American Heart Association (AHA) meeting did not disappoint as the highly anticipated results of the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial were presented. This NIH-funded global study focused on patients with myocardial ischemia documented by non-invasive functional testing, with 5,179 patients undergoing randomization (from 8,518 enrolled patients). It was conducted at 320 sites in 37 countries, and key findings were that:

Beyond these important results, what really caught my attention was that the ISCHEMIA investigators relied on coronary CT angiography (CCTA) to select patients and stratify risk. Incredible work was done to enroll patients with stable symptoms and moderate-to-severe myocardial ischemia in the trial, but the investigators rightly asked, “Can all of the enrolled patients safely be randomized?”

To answer that question, approximately 73% of patients underwent a blinded CCTA to determine who could and could not be randomized between ISCHEMIA’s revascularization and OMT-only arms. The impact is seen here:

Based on the CCTA, the investigators excluded 434 patients who had unprotected left-main disease and another 1,218 patients who had no obstructive coronary disease despite having ischemia on non-invasive testing. This reinforces that CCTA informs clinicians in a manner that other diagnostic modalities simply cannot.

While we wait for published details of the ISCHEMIA trial findings to inform us more fully, many conversations have already turned toward the implications this trial will have on conventional non-invasive cardiac ischemia testing.

A question at the core of this discussion is “If functional stress testing doesn’t effectively guide treatment (i.e. help to select patients whose outcomes will improve with invasive treatment), why are we doing so many stress tests?”

Already, we know an important piece of the path forward will be to identify and effectively assess coronary anatomy and patient risk, as CCTA did in this trial. Such a path will be better for:

  1. Patients, as they get cardiac treatments they need and avoid what they don’t.
  2. Physicians, as they approach clinical decisions for challenging CV cases with better information.
  3. The health care system, as improved application of cardiac testing and treatments delivers efficiencies and savings that we need today.

The ISCHEMIA trial findings will play an important role as patient pathways move beyond stress tests focused on myocardial function and integrate a focus on lesion-specific anatomy and function through a CCTA+FFRCT guided pathway.

See Presentation

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.